Heparin-induced thrombocytopenia pathophysiology: Difference between revisions

Jump to navigation Jump to search
m (Protected "Heparin-induced thrombocytopenia pathophysiology": Robot: Protecting all pages from category Drugs ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
No edit summary
 
(15 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
{{Heparin-induced thrombocytopenia}}
{{Heparin-induced thrombocytopenia}}
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh@perfuse.org]
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] {{shyam}}
 
==Overview==
==Overview==
[[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It is caused by antibodies to complexes between [[heparin]] and [[platelet factor 4]] (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of [[platelet]] and [[endothelium]].
[[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. Heparin exposure triggers the release of [[PF4]] from [[Endothelial|endothelial surfaces]]. Complexes of [[heparin]] and [[PF4]] serve as [[neoepitopes]], or new antigens, and can induce production of antibodies, since this large complex serves as an unfamiliar antigen to the body. Binding of [[IgG]] from the large complexes into the [[Fc immunoglobulin|Fc gamma]] RII receptors triggers activation of the target cells containing the receptors and eventual release of platelet microparticles. This results in production of [[thrombin]], which is highly thrombogenic and contributes to clot formation. Ultimately, this leads to [[thrombotic]] complications in the venous and arterial systems.


==Pathophysiology==
==Pathophysiology==
An understanding of the pathophysiology of HIT requires an understanding of normal physiology.


* It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4).  
'''Normal physiology:'''
* More than 90% patients have these anti–PF4-heparin antibodies in their plasma.
* Under normal circumstances, [[platelet factor 4]] ([[PF4]]) is synthesized by [[platelet]] precursors called [[megakaryocytes]].<ref name="pmid20059332">{{cite journal| author=Arepally GM, Ortel TL| title=Heparin-induced thrombocytopenia. | journal=Annu Rev Med | year= 2010 | volume= 61 | issue=  | pages= 77-90 | pmid=20059332 | doi=10.1146/annurev.med.042808.171814 | pmc=4153429 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20059332  }} </ref> It is stored in the alpha granules of platelets. It is a positively charged protein that functions to antagonize the effects of heparin-like proteins like [[heparin sulfate]] and [[chondroitin sulfate]] on the cell surface.<ref name="pmid23714311">{{cite journal| author=Lee GM, Arepally GM| title=Diagnosis and management of heparin-induced thrombocytopenia. | journal=Hematol Oncol Clin North Am | year= 2013 | volume= 27 | issue= 3 | pages= 541-63 | pmid=23714311 | doi=10.1016/j.hoc.2013.02.001 | pmc=3668315 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23714311  }} </ref> [[PF4]] is located intracellularly, but upon platelet activation, [[PF4]] is released. Since is it a positively charged protein, it binds to negatively charged [[glycosaminoglycans]], such as [[heparan sulfate]].
* These antibodies bind to the platelet's surface and induce their activation by cross-linking Fc IIA receptors and bind to the surface of the endothelium, inducing procoagulant activity.
* Under normal circumstances, [[antithrombin]] is then displaced from [[heparan sulfate]], resulting in the normal desired coagulation.<ref name="pmid20059332">{{cite journal| author=Arepally GM, Ortel TL| title=Heparin-induced thrombocytopenia. | journal=Annu Rev Med | year= 2010 | volume= 61 | issue=  | pages= 77-90 | pmid=20059332 | doi=10.1146/annurev.med.042808.171814 | pmc=4153429 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20059332  }} </ref> [[PF4]] thus contributes to the release of [[antithrombin]] from the cell surface, promoting clotting (platelet plugging).
* Platelets activated with these antibodies, increase their release of platelet factor 4 (PF4). Thus, a viscous cycle continues.
* Under normal circumstances, there are no endogenous antibodies to [[PF4]].
* Under normal circumstances, exogenous [[heparin]] administration results in activation of [[antithrombin III]], which in turn inhibits f[[Coagulation factors|actors II, IX, X, XI, XII, and XIII]]. The allows for adequate [[anticoagulation]] for patients.
 
'''Pathophysiology:'''
* This begins with heparin exposure, which can trigger the release of [[PF4]] from [[Endothelial|endothelial surfaces]]. Heparin can then form ultra-large multimolecular complexes with [[PF4]] via electrostatic forces.<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-e530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=3278058 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270  }} </ref> The epitopes of [[PF4]] that are known to bind to heparin include proline-37 and proline-34.<ref name="pmid24992313">{{cite journal| author=McKenzie SE, Sachais BS| title=Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. | journal=Curr Opin Hematol | year= 2014 | volume= 21 | issue= 5 | pages= 380-7 | pmid=24992313 | doi=10.1097/MOH.0000000000000066 | pmc=4232774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24992313  }} </ref><ref name="pmid12871282">{{cite journal |vauthors=Chong BH |title=Heparin-induced thrombocytopenia |journal=J. Thromb. Haemost. |volume=1 |issue=7 |pages=1471–8 |date=July 2003 |pmid=12871282 |doi= |url=}}</ref>
* These complexes of heparin and [[PF4]] serve as neoepitopes, or new antigens, and can induce production of [[antibodies]], since this large complex serves as an unfamiliar [[antigen]] to the body.<ref name="pmid23714311">{{cite journal| author=Lee GM, Arepally GM| title=Diagnosis and management of heparin-induced thrombocytopenia. | journal=Hematol Oncol Clin North Am | year= 2013 | volume= 27 | issue= 3 | pages= 541-63 | pmid=23714311 | doi=10.1016/j.hoc.2013.02.001 | pmc=3668315 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23714311  }} </ref> [[IgG]] antibodies are typically produced to the multimolecular complexes.<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-e530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=3278058 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270  }} </ref><ref name="pmid17823223">{{cite journal |vauthors=Ahmed I, Majeed A, Powell R |title=Heparin induced thrombocytopenia: diagnosis and management update |journal=Postgrad Med J |volume=83 |issue=983 |pages=575–82 |date=September 2007 |pmid=17823223 |pmc=2600013 |doi=10.1136/pgmj.2007.059188 |url=}}</ref>
* Immune complexes eventually form within a few days of exposure to heparin. The immune complexes consist of heparin, [[PF4]] and [[IgG]].<ref name="pmid23714311">{{cite journal| author=Lee GM, Arepally GM| title=Diagnosis and management of heparin-induced thrombocytopenia. | journal=Hematol Oncol Clin North Am | year= 2013 | volume= 27 | issue= 3 | pages= 541-63 | pmid=23714311 | doi=10.1016/j.hoc.2013.02.001 | pmc=3668315 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23714311  }} </ref> The [[crystallized fragment]] domain, or ([[Fc]]) domain of [[IgG]] can bind to [[Fc receptors]], such as FC gamma RII, on the surface of a variety of immune cells, including [[platelets]], [[Neutrophil|neutrophils]], and [[monocytes]].  
* Binding of [[IgG]] from the large complexes into the Fc gamma RII receptors triggers activation of the target cells containing the receptors and eventual release of [[platelet]] microparticles. This results in production of [[thrombin]], which is highly [[Thrombogenicity|thrombogenic]] and contributes to clot formation.<ref name="pmid23714311">{{cite journal| author=Lee GM, Arepally GM| title=Diagnosis and management of heparin-induced thrombocytopenia. | journal=Hematol Oncol Clin North Am | year= 2013 | volume= 27 | issue= 3 | pages= 541-63 | pmid=23714311 | doi=10.1016/j.hoc.2013.02.001 | pmc=3668315 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23714311  }} </ref> It also leads to production of platelet-fibrin thrombi.<ref name="pmid24992313">{{cite journal| author=McKenzie SE, Sachais BS| title=Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. | journal=Curr Opin Hematol | year= 2014 | volume= 21 | issue= 5 | pages= 380-7 | pmid=24992313 | doi=10.1097/MOH.0000000000000066 | pmc=4232774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24992313  }} </ref><ref name="pmid12752095">{{cite journal |vauthors=Warkentin TE |title=Heparin-induced thrombocytopenia: pathogenesis and management |journal=Br. J. Haematol. |volume=121 |issue=4 |pages=535–55 |date=May 2003 |pmid=12752095 |doi= |url=}}</ref>
* Widespread systemic [[thrombosis]] can lead to significant [[morbidity]] and [[mortality]].


==Reference==
==Reference==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Drugs]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Up-To-Date]]
 
{{WS}}
{{WH}}

Latest revision as of 15:37, 9 August 2018

Heparin-induced thrombocytopenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Heparin-induced thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Heparin-induced thrombocytopenia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heparin-induced thrombocytopenia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heparin-induced thrombocytopenia pathophysiology

CDC on Heparin-induced thrombocytopenia pathophysiology

Heparin-induced thrombocytopenia pathophysiology in the news

Blogs on Heparin-induced thrombocytopenia pathophysiology

Directions to Hospitals Treating Heparin-induced thrombocytopenia

Risk calculators and risk factors for Heparin-induced thrombocytopenia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2] Shyam Patel [3]

Overview

Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. Heparin exposure triggers the release of PF4 from endothelial surfaces. Complexes of heparin and PF4 serve as neoepitopes, or new antigens, and can induce production of antibodies, since this large complex serves as an unfamiliar antigen to the body. Binding of IgG from the large complexes into the Fc gamma RII receptors triggers activation of the target cells containing the receptors and eventual release of platelet microparticles. This results in production of thrombin, which is highly thrombogenic and contributes to clot formation. Ultimately, this leads to thrombotic complications in the venous and arterial systems.

Pathophysiology

An understanding of the pathophysiology of HIT requires an understanding of normal physiology.

Normal physiology:

Pathophysiology:

  • This begins with heparin exposure, which can trigger the release of PF4 from endothelial surfaces. Heparin can then form ultra-large multimolecular complexes with PF4 via electrostatic forces.[3] The epitopes of PF4 that are known to bind to heparin include proline-37 and proline-34.[4][5]
  • These complexes of heparin and PF4 serve as neoepitopes, or new antigens, and can induce production of antibodies, since this large complex serves as an unfamiliar antigen to the body.[2] IgG antibodies are typically produced to the multimolecular complexes.[3][6]
  • Immune complexes eventually form within a few days of exposure to heparin. The immune complexes consist of heparin, PF4 and IgG.[2] The crystallized fragment domain, or (Fc) domain of IgG can bind to Fc receptors, such as FC gamma RII, on the surface of a variety of immune cells, including platelets, neutrophils, and monocytes.
  • Binding of IgG from the large complexes into the Fc gamma RII receptors triggers activation of the target cells containing the receptors and eventual release of platelet microparticles. This results in production of thrombin, which is highly thrombogenic and contributes to clot formation.[2] It also leads to production of platelet-fibrin thrombi.[4][7]
  • Widespread systemic thrombosis can lead to significant morbidity and mortality.

Reference

  1. 1.0 1.1 Arepally GM, Ortel TL (2010). "Heparin-induced thrombocytopenia". Annu Rev Med. 61: 77–90. doi:10.1146/annurev.med.042808.171814. PMC 4153429. PMID 20059332.
  2. 2.0 2.1 2.2 2.3 Lee GM, Arepally GM (2013). "Diagnosis and management of heparin-induced thrombocytopenia". Hematol Oncol Clin North Am. 27 (3): 541–63. doi:10.1016/j.hoc.2013.02.001. PMC 3668315. PMID 23714311.
  3. 3.0 3.1 Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S; et al. (2012). "Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e495S–e530S. doi:10.1378/chest.11-2303. PMC 3278058. PMID 22315270.
  4. 4.0 4.1 McKenzie SE, Sachais BS (2014). "Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia". Curr Opin Hematol. 21 (5): 380–7. doi:10.1097/MOH.0000000000000066. PMC 4232774. PMID 24992313.
  5. Chong BH (July 2003). "Heparin-induced thrombocytopenia". J. Thromb. Haemost. 1 (7): 1471–8. PMID 12871282.
  6. Ahmed I, Majeed A, Powell R (September 2007). "Heparin induced thrombocytopenia: diagnosis and management update". Postgrad Med J. 83 (983): 575–82. doi:10.1136/pgmj.2007.059188. PMC 2600013. PMID 17823223.
  7. Warkentin TE (May 2003). "Heparin-induced thrombocytopenia: pathogenesis and management". Br. J. Haematol. 121 (4): 535–55. PMID 12752095.

Template:WS Template:WH